Generic Versions Of Biotechnology Drugs Allowed
Senate Measure Would Allow Generic Versions Of Biotechnology Drugs After Five Years
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday (March 26, 2009) introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
President Obama has emphasized the need for generic competition in the biotech industry and has estimated that it could save $9.2 billion over 10 years, which could be used to finance his health care reform plan. A similar bill passed by the Senate Health, Education, Labor and Pensions Committee last year would have given biotech products 12 years of exclusivity, but it died without being voted on by the full Senate.
Read More
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
Sens. Charles Schumer (D-N.Y.) and Susan Collins (R-Maine) on Thursday (March 26, 2009) introduced legislation (S 726) that would allow FDA to approve generic versions of biotechnology drugs after a five-year period of brand-name patent exclusivity, the New York Times reports.
President Obama has emphasized the need for generic competition in the biotech industry and has estimated that it could save $9.2 billion over 10 years, which could be used to finance his health care reform plan. A similar bill passed by the Senate Health, Education, Labor and Pensions Committee last year would have given biotech products 12 years of exclusivity, but it died without being voted on by the full Senate.
Read More
Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News
Labels: Arizona, Arizona Biotech, Biotech, Biotechnology drugs
posted by Bill Austin - Generic Versions Of Biotechnology Drugs Allowed
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home